AstraZeneca Pharma India maintains growth momentum with a strong start to FY2026–27, driven by the strength of our portfolio

Q1 FY2026–27 performance reflects disciplined execution across core therapy areas, important regulatory milestones and strategic partnerships that are helping expand access to innovative healthcare solutions in India

10 August 2026: AstraZeneca Pharma India Limited ("the Company"), a science-led biopharmaceutical company, today announced its financial results for the quarter ended June 30, 2026, reporting 30% growth in total revenue from operations to INR 6,828 Mn in Q1 FY2026–27. The Company’s performance was driven by continued momentum across its core therapy areas-- Oncology, Biopharmaceuticals (CVRM and R&I) and Rare Disease, reflecting the strength of its innovation-led strategy, disciplined execution and focus on improving patient outcomes in India.

During the quarter, the Company strengthened its portfolio through key regulatory approvals, expanded scientific engagement through targeted capability-building initiatives and advanced strategic partnerships that support earlier diagnosis and broader access. These developments reflect AstraZeneca Pharma India’s continued focus on addressing unmet medical needs, deepening its presence across priority therapy areas and creating long-term value through science, innovation and sustainable growth.

Financial performance summary:

Bhavana Agrawal, Chief Financial Officer & Director of the Company, said, "We delivered 30% growth in the first quarter, bringing our revenue to INR 6,828 Mn. This performance builds on our strong track record of delivering a consistent double-digit growth over the last four years. Our focus remains on investing strategically in opportunities that support sustainable long-term value creation."

Mr. Praveen Rao Akkinepally, Country President & Managing Director, AstraZeneca Pharma India Ltd., added, "Our purpose is to push the boundaries of science to deliver life-changing medicines, and this shapes how we serve unmet patient needs in India. The growth and momentum in the first quarter reflects the strength of our portfolio and focus on expanding access to serve more patients in India."

Key milestones:  

• Acalabrutinib – Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL): Received regulatory approval for acalabrutinib in combination with venetoclax with or without obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL).
• Acalabrutinib – Mantle cell lymphoma (MCL): Received regulatory approval for acalabrutinib in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant (ASCT).
• Trastuzumab deruxtecan – HER2-positive breast cancer: Received regulatory approval for trastuzumab deruxtecan in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+ or ISH+) breast cancer.

Strategic initiatives:

• Government of Telangana MoU – AI-enabled lung cancer screening: Signed a Memorandum of Understanding with the Government of Telangana to introduce AI-enabled lung cancer screening across public healthcare facilities in the state. Under the collaboration, AstraZeneca will facilitate deployment of Qure.ai’s AI-powered chest X-ray solution to support clinicians in identifying high-risk pulmonary nodules and other lung conditions, enabling earlier triage and follow-up. The initiative is expected to roll out across 20 public health facilities spanning urban and rural settings and includes training and upskilling of healthcare professionals to support effective and sustainable adoption.
• K+ Connect – Hyperkalaemia management in Heart Failure and Chronic Kidney Disease: Launched K+ Connect, a pan-India multidisciplinary initiative focused on advancing the management of hyperkalaemia among patients living with heart failure and chronic kidney disease. The initiative brings together clinicians across specialties to support a more coordinated approach towards risk identification, monitoring and management of hyperkalaemia.
• India Coronary Conquest (ICC) 2026 – Advancing cardiovascular care: Launched India Coronary Conquest 2026 in collaboration with STEMI India, a clinician-led national complex PCI challenge designed to strengthen evidence-based learning and peer exchange among interventional cardiologists. The initiative aims to support capability building in advanced cardiovascular care through case-based learning and scientific collaboration.

Recognitions:

• OPPI India Awards 2026: AstraZeneca Pharma India received the Medical Excellence Award for its contributions to Rare Disease and was named Runner-up in the Marketing Excellence category for its Hyperkalaemia & Kidney Care initiative in Biopharmaceuticals.
• ETHRWorld Employee Experience Awards 2026: AstraZeneca Pharma India was awarded the Gold Award in the Exceptional Employee Experience in Driving Business Impact category, recognising its commitment to fostering a high-performing, collaborative and purpose-driven workplace.